Review: In dyslipidemia or atherosclerotic CVD, alirocumab and evolocumab vs control each reduce MI and stroke. Smith DA. Ann Intern Med 2019;171:JC56.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Smith DA. Review: In dyslipidemia or atherosclerotic CVD, alirocumab and evolocumab vs control each reduce MI and stroke. Ann Intern Med 2019;171:JC56.
PMID: 31739339